We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Glioma Risk Lower with Elevated Blood Sugar

By LabMedica International staff writers
Posted on 16 May 2017
Print article
Image: New research suggests that there may be a link between blood sugar and glioma (Photo courtesy of MNT).
Image: New research suggests that there may be a link between blood sugar and glioma (Photo courtesy of MNT).
While many cancers are more common among those with diabetes, cancerous brain tumors called gliomas are less common among those with elevated blood sugar and diabetes.

Glioma is a heterogeneous primary brain tumor for which there is no treatment that ensures long-term survival and patients diagnosed with the most common adult form of this tumor, glioblastoma, survive on average only 14 months.

An international team of scientists led by those at the Ohio State University evaluated blood sugar and diabetes data and its relationship to subsequent development of brain cancer and found that those with elevated blood sugar and diabetes had a lower risk of developing glioma. They used data from the Apolipoprotein MOrtality RISk (AMORIS) (n = 528,580) and the Metabolic syndrome and Cancer project (Me-Can) cohorts (n = 269,365). They identified individuals who were followed for a maximum of 15 years after their first blood glucose test until glioma diagnosis, death, emigration or the end of follow-up.

They conducted an exploratory analysis of the 51 glioma cases using the Me-Can data set with multiple measurements to determine whether glucose values equal to or less than 7.0 mmol/L varied with the number of measurements or time between the blood glucose test and glioma diagnosis. They found that fasting and non-fasting glucose dose-response relationships were similar allowing them to combine data from these two groups.

They found that the relative proportions of male and female total glioma cases differ between the cohorts (in AMORIS 65% are men; in Me-Can 52%), as does fasting status (in AMORIS 61% of blood was drawn when total glioma cases were fasting; in Me-Can all blood samples were collected from fasting participants). Pre-diagnostic blood glucose levels were inversely related to glioma risk and pre-diagnostic diabetes. During the year before diagnosis, blood glucose was inversely associated with glioma in the AMORIS but not the Me-Can cohort. This AMORIS result is consistent with their hypothesis that excess glucose consumption by the preclinical tumor accounts for the inverse association between blood glucose and glioma.

Judith Schwartzbaum, PhD, a professor and lead author of the study said, “Diabetes and elevated blood sugar increase the risk of cancer at several sites including the colon, breast and bladder. But in this case, these rare malignant brain tumors are more common among people who have normal levels of blood glucose than those with high blood sugar or diabetes.” The study was published on May 3, 2017, in the journal Scientific Reports.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more